Empowering Diagnostic Labs in Oncology: Benchmarking Biomarker-Driven Therapies

Chen Yeh^*
OncoDxRx, Los Angeles, CA, USA.

Correspondence to: Chen Yeh, OncoDxRx LLC, 150 N Santa Anita Ave., Suite 300, Los Angeles, CA 91006, USA.
Received date: September 02, 2024; Accepted date: September 13, 2024; Published date: September 20, 2024
Citation: Yeh C. Empowering Diagnostic Labs in Oncology: Benchmarking Biomarker-Driven Therapies. J Med Res Surg. 2024;5(5):101-103. doi: 10.52916/jmrs244146
Copyright: ©2024 Yeh C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Abstract

In the past decade, oncology care has witnessed a transformative shift, significantly propelled by the growing field of precision medicine. This revolution has been catalyzed by a deeper understanding of cancer’s underlying biological drivers, unveiling new avenues to combat this multifaceted disease. For instance, the identification and targeting of the EGFR mutations have paved the way for personalized therapies in Non-Small Cell Lung Cancer (NSCLC).
Traditionally, diagnostic labs played a more reserved, albeit crucial, role in the healthcare continuum, primarily focusing on providing diagnostic services. However, as further insights into cancer’s molecular intricacies emerge, biomarkers have become central to the endeavor of tailoring treatments to individual patients’ genetic and molecular profiles. This rising significance of biomarkers has recalibrated the role of and expectations from diagnostic labs, ushering them into a more proactive and collaborative role in oncology care.
The shift from a one-size-fits-all approach to a more personalized, biomarker-driven therapeutic strategy in oncology has shown promise in enhancing treatment outcomes for patients and streamlining the drug development and approval processes for pharmaceutical industry. As biomarker knowledge expands, the traditional diagnostic lab has transitioned from a vendor of testing services to a strategic partner in drug development and clinical implementation.

Keywords:

Oncology, Precision medicine, Diagnostic labs, Biomarker, Drug development.

References

1. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101-126.
2. SDang TO, Ogunniyi A, Barbee MS, et al. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16(1):13-20.
3. SYeh C. Advancing biomarker testing for precision cancer care. Mathews J Cancer Sci. 2023;8(4):46.
4. SYe J-S, Lin S-T. Narrowing time to treatment initiation in non-small cell lung cancer-cell-free DNA profiling at the time of biopsy. ES J Oncol. 2022;2(1):1006.
5. SLin S-T, Lai H-C, Yeh C. Single-tube two-pronged approach using both cell-free DNA and RNA for multimodal biomarker tests at the time of biopsy. Precis Med Sci. 2023;12(4):233-241.
6. SLai H-C, Kuo W-H, Yeh C. Oncology breakthroughs to a new pace of precision diagnostics and therapeutics. Appl Med Res. 2023;10(2):1-6.